High antiphospholipid antibody levels are associated with statin use and may reflect chronic endothelial damage in non-autoimmune thrombosis: Cross-sectional study

Journal of Clinical Pathology

Volumn 65, Issue 6, 2012, Pages 551-556

  Broder, Anna ^a   Tobin, Jonathan N ^a,b   Putterman, Chaim ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Clinical Directors Network   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHOSPHOLIPID ANTIBODY; WARFARIN;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CROSS-SECTIONAL STUDY; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DRUG USE; FEMALE; HOSPITAL ADMISSION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

AGED; ANTIBODIES, ANTIPHOSPHOLIPID; ASPIRIN; BIOLOGICAL MARKERS; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LUPUS COAGULATION INHIBITOR; MALE; MIDDLE AGED; PULMONARY EMBOLISM; RISK FACTORS; STROKE; VENOUS THROMBOSIS; WARFARIN;

EID: 84861807307     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2011-200613     Document Type: Article

References (34)

1. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002;346:752-63. (Pubitemid 34983997)
2. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
3. Palomo I, Segovia F, Ortega C, et al. Antiphospholipid syndrome: a comprehensive review of a complex and multisystemic disease. Clin Exp Rheumatol 2009;27:668-77.
4. Erkan D, Lockshin MD. New approaches for managing antiphospholipid syndrome. Nat Clin Pract Rheumatol 2009;5:160-70.
5. Meroni PL, Riboldi P. Pathogenic mechanisms mediating antiphospholipid syndrome. Curr Opin Rheumatol 2001;13:377-82. (Pubitemid 32929866)
6. Bordin G, Boldorini R, Meroni PL. The two hit hypothesis in the antiphospholipid syndrome: acute ischaemic heart involvement after valvular replacement despite anticoagulation in a patient with secondary APS. Lupus 2003;12:851-3. (Pubitemid 37463103)
7. Barbhaiya M, Erkan D. Primary thrombosis prophylaxis in antiphospholipid antibody-positive patients: where do we stand? Curr Rheumatol Rep 2011;13:59-69.
8. Galli M, Barbui T. Antiphospholipid antibodies and thrombosis: strength of association. Hematol J 2003;4:180-6. (Pubitemid 36789972)
9. Erkan D, Lockshin MD. Antiphospholipid syndrome. Curr Opin Rheumatol 2006;18:242-8. (Pubitemid 43740374)
10. Derksen RH, de Groot PG. Towards evidence-based treatment of thrombotic antiphospholipid syndrome. Lupus 2010;19:470-4.
11. Petri M. Evidence-based management of thrombosis in the antiphospholipid antibody syndrome. Curr Rheumatol Rep 2003;5:370-3.
12. Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995;332:993-7.
13. Erkan D, Yazici Y, Peterson MG, et al. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford) 2002;41:924-9.
14. Greco TP, Conti-Kelly AM, Matsuura E, et al. Antiphospholipid antibodies in patients with coronary artery disease: new cardiac risk factors? Ann NY Acad Sci 2007;1108:466-74. (Pubitemid 47528760)
15. Neville C, Rauch J, Kassis J, et al. Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies. Thromb Haemost 2003;90:108-15. (Pubitemid 36873866)
16. Ruffatti A, Del Ross T, Ciprian M, et al. Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study. Ann Rheum Dis 2009;68:397-9.
17. Roubey RA. Risky business: the interpretation, use, and abuse of antiphospholipid antibody tests in clinical practice. Lupus 2010;19:440-5.
18. Marai I, Shechter M, Langevitz P, et al. Anti-cardiolipin antibodies and endothelial function in patients with coronary artery disease. Am J Cardiol 2008;101:1094-7.
19. Erkan D, Harrison MJ, Levy R, et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 2007;56:2382-91. (Pubitemid 47173586)
20. Bellin E, Fletcher DD, Geberer N, et al. Democratizing information creation from health care data for quality improvement, research, and education-the Montefiore Medical Center Experience. Acad Med 2010;85:1362-8.
21. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
22. Lemeshow S, Hosmer DW Jr. A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol 1982;115:92-106. (Pubitemid 12205725)
23. Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun 2000;15:145-51.
24. Ferrara DE, Swerlick R, Casper K, et al. Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. J Thromb Haemost 2004;2:1558-63. (Pubitemid 40186171)
25. Ferrara DE, Liu X, Espinola RG, et al. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum 2003;48:3272-9. (Pubitemid 37409342)
26. Ferrara DE, Pierangeli SS. Diverse effects of statins on endothelial cells? Thromb Haemost 2005;93:186-8. (Pubitemid 40253718)
27. Jajoria P, Murthy V, Papalardo E, et al. Statins for the treatment of antiphospholipid syndrome? Ann NY Acad Sci 2009;1173:736-45.
28. Boden WE. Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management. Curr Opin Cardiol 2003;18:278-85. (Pubitemid 37041048)
29. Corrado E, Rizzo M, Coppola G, et al. An update on the role of markers of inflammation in atherosclerosis. J Atheroscler Thromb 2010;17:1-11.
30. Blaha MJ, Budoff MJ, DeFilippis AP, et al. Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study. Lancet 2011;378:684-92.
31. Pengo V, Banzato A, Bison E, et al. Antiphospholipid syndrome: critical analysis of the diagnostic path. Lupus 2010;19:428-31.
32. Coull BM, Levine SR, Brey RL. The role of antiphospholipid antibodies in stroke. Neurol Clin 1992;10:125-43.
33. Ginsberg JS, Wells PS, Brill-Edwards P, et al. Antiphospholipid antibodies and venous thromboembolism. Blood 1995;86:3685-91.
34. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.